Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Qun Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8638-2908; OpenAlex author ID A5100336666. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2019: 2 papers · 2020: 6 papers · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 4 papers

Papers 20

  1. Exploring the biological mechanism and clinical value of perineural invasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217515↗
  2. Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance. Co-author DOI 10.1016/j.seminoncol.2025.152338↗
  3. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  4. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. First author DOI 10.1038/s41419-025-07740-8↗
  5. Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling. Co-author DOI 10.1002/mc.23699↗
  6. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  7. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  8. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  9. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Co-author DOI 10.1155/2021/6530298↗
  10. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  11. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  12. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.800268↗
  13. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  14. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  15. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. First author DOI 10.1038/s41419-020-2475-3↗
  16. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  17. Optimization of internal reference genes for qPCR in human pancreatic cancer research. Co-author DOI 10.21037/tcr.2020.02.48↗
  18. LncRNA KCNK15-AS1 inhibits pancreatic cancer progression by promoting the expression of its binding protein ACTR3B Co-author DOI 10.21203/rs.3.rs-55282/v1↗
  19. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  20. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 17 shared papers, 2019–2025 · strength 2.41
  2. Xumin Huang · 13 shared papers, 2019–2025 · strength 1.76
  3. Peng Shen · 13 shared papers, 2019–2025 · strength 1.70
  4. Wanli Ge · 13 shared papers, 2019–2025 · strength 1.68
  5. Lingdong Meng · 12 shared papers, 2019–2025 · strength 1.55
  6. Hao Yuan · 11 shared papers, 2019–2025 · strength 1.37
  7. Yi Miao · 10 shared papers, 2019–2022 · strength 1.08
  8. Guodong Shi · 8 shared papers, 2020–2025 · strength 0.99
  9. Yi Miao · 5 shared papers, 2020–2025 · strength 0.82
  10. Pengfei Wu · 5 shared papers, 2021–2024 · strength 0.76
  11. Taoyue Yang · 6 shared papers, 2021–2022 · strength 0.75
  12. Zipeng Lu · 6 shared papers, 2020–2022 · strength 0.69
  13. Pengfei Wu · 6 shared papers, 2020–2022 · strength 0.65
  14. Lei Chen · 5 shared papers, 2019–2025 · strength 0.61
  15. Yufeng Zhang · 2 shared papers, 2025 · strength 0.47
  16. Hao Yuan · 2 shared papers, 2025 · strength 0.47
  17. Baobao Cai · 4 shared papers, 2020–2022 · strength 0.46
  18. Kuirong Jiang · 3 shared papers, 2020–2025 · strength 0.43
  19. Jingjing Zhang · 4 shared papers, 2019–2020 · strength 0.41
  20. Shouji Cao · 3 shared papers, 2020–2021 · strength 0.31
  21. Yang Wu · 1 shared paper, 2025 · strength 0.24
  22. Min Tu · 2 shared papers, 2020–2022 · strength 0.23
  23. Pengfei Wu · 1 shared paper, 2025 · strength 0.23
  24. Xinjian Liu · 1 shared paper, 2025 · strength 0.23
  25. Meng Cao · 2 shared papers, 2020–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.